Print

Purpose

The purpose of this study is to measure, monitor, and analyze long term effects of SARS-CoV-2. The main purpose is to assess the post-hospitalization outcomes of patients who were diagnosed with SAR-CoV-2 by comparing to patients who were hospitalized with an acute neurological disease.

Conditions

Eligibility

Eligible Ages
Over 18 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Control Participants: Males and females over the age of 18 years hospitalized and receiving intensive care for diagnosis's other than COVID-19 or an acute neurological disease and who were not diagnosed (clinically or with PCR testing) with COVID-19. - Case Participants: Males and females over the age of 18 years who had been hospitalized at Mayo Clinic Hospital for treatment of COVID-19 confirmed by PCR test. - We acknowledge that some participants may be unable to consent due to underlying medical conditions; an eligible proxy may provide the informed consent and provide a signature on the designated line. - Women of childbearing age, between the ages of 18 to 55, must complete a negative pregnancy test. - Minority individuals over the age of 18 years will be eligible to enroll.

Exclusion Criteria

  • Males and females, under the age of 18 years. - Participants with PET/MRI non-compatible devices. - Claustrophobia. - Allergies to study related procedures. - Pregnant , incarcerated, or institutionalized subjects will not be included in the study.

Study Design

Phase
Study Type
Observational
Observational Model
Case-Control
Time Perspective
Prospective

Arm Groups

ArmDescriptionAssigned Intervention
Non-COVID-19 Diagnosis Control Group Subjects hospitalized and receiving intensive care for diagnosis of an acute neurological disease other than COVID-19
  • Drug: (R)-1-(2-chlorophenyl)- N-[11C] ([11C] PK11195)
    Radiotracer used during the PET-MR scan of the study to identify signs of disease. Used in studies related to Alzheimer's disease. Only FDA approved for investigational use.
  • Drug: 2-(4-[11C]methylamino phenyl)-6-hydroxybenzothiazole (11C]6-OH-BTA-1 or [11C]PIB)
    Radiotracer used during the PET-MR scan of the study to identify signs of disease. Used in studies related to Alzheimer's disease. Only FDA approved for investigational use.
COVID-19 Diagnosis Case Group Subjects previously hospitalized at Mayo Clinic Hospital for treatment of PCR test confirmed COVID-19
  • Drug: (R)-1-(2-chlorophenyl)- N-[11C] ([11C] PK11195)
    Radiotracer used during the PET-MR scan of the study to identify signs of disease. Used in studies related to Alzheimer's disease. Only FDA approved for investigational use.
  • Drug: 2-(4-[11C]methylamino phenyl)-6-hydroxybenzothiazole (11C]6-OH-BTA-1 or [11C]PIB)
    Radiotracer used during the PET-MR scan of the study to identify signs of disease. Used in studies related to Alzheimer's disease. Only FDA approved for investigational use.

Recruiting Locations

More Details

NCT ID
NCT05220514
Status
Completed
Sponsor
Mayo Clinic

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.